Gilead Sciences has formed an agreement with Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, under which Gilead has received an exclusive license to develop and commercialize products incorporating Theraclone's broadly neutralizing HIV-antibodies for therapeutic applications in HIV. These broadly neutralizing antibodies were discovered in collaboration with the International AIDS Vaccine Initiative and The Scripps Research Institute using Theraclone's proprietary I-STAR, which allows for the rapid testing of fully human antibodies for assessing their biologic function and activity.

Under the terms of the agreement, Theraclone received an upfront payment and is eligible to receive additional payments based upon achievement of certain development and commercialization milestones.

Source: Theraclone Sciences